1. PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.
- Author
-
da Silva ALL, de Araújo TPG, de Albuquerque Ferreira SC, Leite AB, da Silva JKS, Albuquerque LWN, de Lima ARV, Barros HCS, Silva LR, da Silva-Júnior EF, de Araújo-Júnior JX, Neto VM, de Queiroz AC, and Alexandre-Moreira MS
- Subjects
- Humans, Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositol 3-Kinases metabolism, Signal Transduction, Glioblastoma drug therapy, Glioblastoma genetics, Glioblastoma metabolism, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Brain Neoplasms pathology
- Abstract
Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF